A pilot study for screening blood donors in Taiwan by nucleic acid amplification technology: detecting occult hepatitis B virus infections and closing the serologic window period for hepatitis C virus
Authors:
- 14 April 2008
- journal article
- Published by Wiley in Transfusion
- Vol. 48 (6) , 1198-1206
Abstract
BACKGROUND: Blood donors in Taiwan currently are screened for hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV) infection by immunoassay. The risk of enzyme immunoassay (EIA)‐negative, nucleic acid amplification technology (NAT)‐reactive donations is not well understood. This study aimed to screen for such donors in Taiwan by a multiplex test (cobas TaqScreen, Roche) on a commercially available NAT system (cobas s 201 system, Roche).STUDY DESIGN AND METHODS: NAT was performed on donors without prescreening in pools of six and NAT‐reactive pools were then resolved to the single donation. Individual‐donor NAT–reactive samples were discriminated by a commercially available polymerase chain reaction (PCR)–based diagnostic assay (COBAS AmpliScreen, Roche). Samples with EIA‐ and NAT‐discordant results were investigated with supplemental serologic and confirmatory tests. Each sample taken from follow‐up of HBV NAT yield cases was tested for HBV serologic profile, NAT, and viral load. The sensitivity and performance efficacy were also evaluated.RESULTS: The 95 percent limit of detection (LOD) for HBV, HCV, and HIV were 5.09, 11.83, and 62.53 IU per mL, respectively. Among 10,727 seronegative donations, 12 HBV NAT yield cases (0.11%) and 1 HCV NAT yield case (0.01%) were detected. Follow‐up results for 1 to 8 months showed that the HCV yield case was a window case and all HBV NAT yield cases were occult carriers.CONCLUSION: The use of NAT detected occult HBV and reduced HCV window period. The yield rate, especially occult HBV, was 10‐ to 100‐fold higher than that in developed, HBV nonendemic countries. Therefore, NAT implementation for routine donor screening in a more cost‐effective manner should contribute to safer blood transfusion in Taiwan.Keywords
This publication has 26 references indexed in Scilit:
- Epidemiology of HBV infection in Asian blood donors: Emphasis on occult HBV infection and the role of NATJournal of Clinical Virology, 2006
- International Forum: 1Vox Sanguinis, 2005
- Impact of nucleic acid amplification technology (NAT) in Italy in the three years following implementation (2001-2003)Eurosurveillance, 2005
- Blood safety and nucleic acid testing in EuropeEurosurveillance, 2005
- Epidemiology of blood donors in Japan, positive for hepatitis B virus and hepatitis C virus by nucleic acid amplification testingVox Sanguinis, 2005
- Occult hepatitis B virus infection: implications in transfusionVox Sanguinis, 2004
- Assessing the accuracy of three viral risk models in predicting the outcome of implementing HIV and HCV NAT donor screening in Australia and the implications for future HBV NATTransfusion, 2002
- US NAT yield: where are we after 2 years?Transfusion Medicine, 2002
- NAT of the United States and Canadian blood supplyTransfusion, 2000
- Epidemiology of hepatitis B virus infection in the Asia–Pacific regionJournal of Gastroenterology and Hepatology, 2000